Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronald D Perrone

Showing results (51-60 of 123) with videos related to

Pageof 13
Sort By:
Clinical Journal of the American Society of Nephrology : CJASN|October 4, 2017
Metabolomic Alterations Associated with Cause of CKDMorgan E Grams, Adrienne Tin, Casey M Rebholz, et al.
Clinical Journal of the American Society of Nephrology : CJASN|February 26, 2016
Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 TrialVicente E Torres, Eiji Higashihara, Olivier Devuyst, et al.
The New England Journal of Medicine|November 6, 2012
Tolvaptan in patients with autosomal dominant polycystic kidney diseaseVicente E Torres, Arlene B Chapman, Olivier Devuyst, et al.
BMC Nephrology|May 27, 2017
The effect of disease severity markers on quality of life in autosomal dominant polycystic kidney disease: a systematic review, meta-analysis and meta-regressionMyrte K Neijenhuis, Wietske Kievit, Ronald D Perrone, et al.
Kidney International Reports|November 17, 2017
Total Kidney Volume Is a Prognostic Biomarker of Renal Function Decline and Progression to End-Stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney DiseaseRonald D Perrone, Mohamad-Samer Mouksassi, Klaus Romero, et al.
Kidney360|July 28, 2021
Association of Baseline Urinary Metabolic Biomarkers with ADPKD Severity in TAME-PKD Clinical Trial ParticipantsKenneth R Hallows, Andrew D Althouse, Hui Li, et al.
Kidney International Reports|November 17, 2017
A Drug Development Tool for Trial Enrichment in Patients With Autosomal Dominant Polycystic Kidney DiseaseRonald D Perrone, Mohamad-Samer Mouksassi, Klaus Romero, et al.
The New England Journal of Medicine|November 7, 2017
Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney DiseaseVicente E Torres, Arlene B Chapman, Olivier Devuyst, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 19, 2015
Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 TrialRon T Gansevoort, Esther Meijer, Arlene B Chapman, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 19, 2016
Tolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease: Secondary Analysis From a Randomized Controlled TrialNiek F Casteleijn, Jaime D Blais, Arlene B Chapman, et al.
Pageof 13

Showing results (51-60 of 123) with videos related to

Sort By:
Pageof 13
Clinical Journal of the American Society of Nephrology : CJASN|October 4, 2017
Metabolomic Alterations Associated with Cause of CKDMorgan E Grams, Adrienne Tin, Casey M Rebholz, et al.
Clinical Journal of the American Society of Nephrology : CJASN|February 26, 2016
Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 TrialVicente E Torres, Eiji Higashihara, Olivier Devuyst, et al.
The New England Journal of Medicine|November 6, 2012
Tolvaptan in patients with autosomal dominant polycystic kidney diseaseVicente E Torres, Arlene B Chapman, Olivier Devuyst, et al.
BMC Nephrology|May 27, 2017
The effect of disease severity markers on quality of life in autosomal dominant polycystic kidney disease: a systematic review, meta-analysis and meta-regressionMyrte K Neijenhuis, Wietske Kievit, Ronald D Perrone, et al.
Kidney International Reports|November 17, 2017
Total Kidney Volume Is a Prognostic Biomarker of Renal Function Decline and Progression to End-Stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney DiseaseRonald D Perrone, Mohamad-Samer Mouksassi, Klaus Romero, et al.
Kidney360|July 28, 2021
Association of Baseline Urinary Metabolic Biomarkers with ADPKD Severity in TAME-PKD Clinical Trial ParticipantsKenneth R Hallows, Andrew D Althouse, Hui Li, et al.
Kidney International Reports|November 17, 2017
A Drug Development Tool for Trial Enrichment in Patients With Autosomal Dominant Polycystic Kidney DiseaseRonald D Perrone, Mohamad-Samer Mouksassi, Klaus Romero, et al.
The New England Journal of Medicine|November 7, 2017
Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney DiseaseVicente E Torres, Arlene B Chapman, Olivier Devuyst, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 19, 2015
Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 TrialRon T Gansevoort, Esther Meijer, Arlene B Chapman, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 19, 2016
Tolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease: Secondary Analysis From a Randomized Controlled TrialNiek F Casteleijn, Jaime D Blais, Arlene B Chapman, et al.
Pageof 13